Close Asset Management
INMB icon

Close Asset Management’s INmune Bio INMB Stock Holding History

Close Asset Management’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3K Hold
2,000
– – ﹤0.01% 251
2026
Q1 		$2K Hold
2,000
– – ﹤0.01% 259
2025
Q4 		$3K Hold
2,000
– – ﹤0.01% 254
2025
Q3 		$4K Buy
+2,000
New +$4.58K ﹤0.01% 248

Other funds holding INMB

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Close Asset Management's INMB Position: Q2 2026 in Review

Close Asset Management held its INmune Bio (INMB) position steady in Q2 2026 at 2,000 shares worth $3K. The position accounts for ﹤0.01% of the portfolio, ranked #251.

Close Asset Management first reported a position in INMB in Q3 2025 and has held it in 4 quarters since. The position peaked at $4K in Q3 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q2 2026.

  • Close Asset Management held 2,000 shares of INmune Bio worth $3K as of Q2 2026.
  • Close Asset Management left its INmune Bio share count unchanged in Q2 2026.
  • INmune Bio made up ﹤0.01% of Close Asset Management's portfolio in Q2 2026, its #251 holding.
  • Close Asset Management first reported a position in INmune Bio in Q3 2025 and has held it in 4 quarters since.
  • Close Asset Management's INmune Bio position peaked at $4K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q2 2026.

Based on Close Asset Management's 13F filing for Q2 2026, filed 11 Aug 2026.